ASH 2025: Promising iadademstat updates

Oryzon Genomics announced the presentation of promising updates for two clinical studies involving iadademstat at the American Society of Hematology (ASH) 67th Annual Meeting. Notably, a Phase Ib trial (ALICE-2) testing the candidate in combination with azacitidine and venetoclax showed a 100% overall response rate (ORR) across 10 newly diagnosed acute myeloid leukaemia (AML) patients, and a composite complete remission (CCR) rate of 90%. The second update corresponds to the lead FRIDA programme (iadademstat plus gilteritinib in FLT3-mutant relapsed/refractory (r/r) AML), showing a CCR rate of 67% across 15 evaluable patients at the selected dose level. Importantly, across both studies, iadademstat was safe and well tolerated, which, alo...